Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Amgn crawled date : 2021 - 04 - 23 save search
Hematology/Oncology (Cancer) Approvals & Safety Notifications
Published: 2021-04-23 (Crawled : 18:42) - fda.gov
LLY | News | $733.27 -1.67% 470K
|
Health Technology
| Email alert
Add to watchlist
RIGL | $1.145 0.44% 92K
|
Health Technology
| Email alert
Add to watchlist
ILMN | $122.54 -1.54% 84K
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.795 -0.4% 1.5M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $143.99 3.6% 53K
|
Health Technology
| Email alert
Add to watchlist
CLVS | $0.0812 -3.94%
|
Health Technology
| Email alert
Add to watchlist
KPTI | $1.135 4.13% 280K
|
Health Technology
| Email alert
Add to watchlist
ALNY | $146.17 0.07% 16K
|
Health Technology
| Email alert
Add to watchlist
PFE | News 4 | $26.21 -0.42% 5M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $168.635 -0.53% 440K
|
Health Technology
| Email alert
Add to watchlist
AGIO | $32.04 0.72% 37K
|
Health Technology
| Email alert
Add to watchlist
VSTM | $9.615 0.05% 5.1K
|
Health Technology
| Email alert
Add to watchlist
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $914.08 0.75% 54K
|
Health Technology
| Email alert
Add to watchlist
AVEO | $15.0 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
YMAB | $15.32 -0.13% 19K
|
Health Technology
| Email alert
Add to watchlist
BPMC | $91.69 -0.65% 14K
|
Health Technology
| Email alert
Add to watchlist
EXEL | $23.55 1.12% 160K
|
Health Technology
| Email alert
Add to watchlist
ADCT | $4.905 -1.31% 41K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.1 -1.24% 260K
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.905 0.13% 270K
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.44 -0.41% 97K
|
Health Technology
| Email alert
Add to watchlist
cancer approval
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
BMY | $48.795 -0.4% 1.5M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
AMGN | News | $273.905 0.13% 270K
|
Health Technology
|
| O: -0.03%
H: 1.24%
C: 0.8%
positive phase 3 psoriasis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
TROO | $1.41 29.36% 280K
|
Manufacturing
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
RCAT | $1.52 26.67% 1.3M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.